Skip to main content

Advertisement

Table 3 Readiness to Perform Visual Analogue Scale

From: Effects of acute ingestion of a pre-workout dietary supplement with and without p-synephrine on resting energy expenditure, cognitive function and exercise performance

Questions Treatment Time (h) p-level
Pre 1 2
I am looking forward to today’s workout PLA 3.67 ± 0.85 3.61 ± 1.00 3.61 ± 0.87 0.21
PWS 3.71 ± 0.77 3.89 ± 0.79 3.65 ± 0.65
PWS + S 3.71 ± 0.99 3.82 ± 1.17 3.51 ± 1.09
I am optimistic about my future performance PLA 3.74 ± 0.83 3.70 ± 0.94 3.78 ± 0.88 0.02q
PWS 3.88 ± 0.69 4.05 ± 0.73 a 3.83 ± 0.70
PWS + S 4.00 ± 0.69 4.21 ± 0.62 a 4.01 ± 0.71
I feel vigorous and energetic PLA 3.23 ± 0.95 3.35 ± 0.90 3.38 ± 1.04 0.001
PWS 3.19 ± 0.89 3.77 ± 0.78 *a 3.33 ± 1.09
PWS + S 3.33 ± 0.77 3.89 ± 0.73 *a 2.96 ± 0.97 a,b
I have little muscle soreness PLA 3.60 ± 0.99 3.42 ± 0.99 3.29 ± 1.01 0.17
PWS 3.54 ± 1.17 3.81 ± 1.35 3.25 ± 1.03
PWS + S 3.13 ± 1.31 3.27 ± 1.28 3.21 ± 1.12
  1. Values are means ± standard deviations. MANOVA analysis revealed overall Wilks’ Lambda treatment (p = 0.03), time (p = 0.01), and treatment x time (p = 0.004). Greenhouse-Geisser linear or quadratic (q) univariate p-levels of interactions (treatment x time) are reported above * represents p < 0.05 difference from baseline. a denotes a significant difference from PLA. b denotes a significant difference from PWS. c denotes a significant difference from PWS + S